Enzyme-based therapeutics (EBTs) have the potential to tap into an almost unmeasurable amount of enzyme biodiversity and treat myriad conditions. Although EBTs were some of the first biologics used clinically, the rate of development of newer EBTs has lagged behind that of other biologics. Here, we review the history of EBTs, and discuss the state of each class of EBT, their potential clinical advantages, and the unique challenges to their development. Additionally, we discuss key remaining technical barriers that, if addressed, could increase the diversity and rate of the development of EBTs.

中文翻译：

---

酶疗法的过去、现在和未来

基于酶的疗法（EBT）有潜力利用几乎无法测量的酶生物多样性并治疗多种疾病。尽管 EBT 是最早应用于临床的生物制剂之一，但新型 EBT 的开发速度已落后于其他生物制剂。在这里，我们回顾了 EBT 的历史，并讨论了每一类 EBT 的现状、它们潜在的临床优势以及它们发展的独特挑战。此外，我们还讨论了剩余的关键技术障碍，如果解决这些障碍，可能会提高 EBT 的多样性和发展速度。